ASCO 2022 Conference Coverage
Playback speed
10 seconds
ASCO 2022 on a Phase I, Open-Label, Dose Escalation, Confirmation, and Expansion Trial of BI 1810631 as Monotherapy in Advanced/Metastatic Solid Tumors With HER2 Aberrations
By
ASCO 2022 Conference Coverage
FEATURING
John Heymach
By
ASCO 2022 Conference Coverage
FEATURING
John Heymach
97 views
June 16, 2022
Login to view comments.
Click here to Login
Lung